From: Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome
Survivors (n = 60) | Non-survivors (n = 54) | p value | |
---|---|---|---|
Antibiotic treatment | 38 (63) | 47 (87) | <0.003a |
Duration of antibiotic treatment, days | 7 ± 8 | 10 ± 10 | 0.197 |
Glycopeptide use | 9 (15) | 11 (20) | 0.225 |
Duration, days | 2 ± 3 | 1 ± 3 | 0.399 |
Extended-spectrum penicillin use | 34 (56) | 38 (70) | 0.099 |
Duration, days | 8 ± 8 | 7 ± 8 | 0.710 |
Fluoroquinolone use | 22 (36) | 24 (44) | 0.336 |
Duration, days | 6 ± 6 | 5 ± 4 | 0.913 |
Extended-spectrum cephalosporin use | 3 (5) | 16 (29) | 0.001b |
Duration, days | 1 ± 3 | 2 ± 5 | 0.002 |
Carbapenem use | 5 (8) | 7 (12) | 0.306 |
Duration, days | 3 ± 3 | 4 ± 1 | 0.428 |
Aminoglycoside use | 10 (16) | 15 (27) | 0.233 |
Duration, days | 2 ± 5 | 2 ± 4 | 0.154 |
Metronidazole use | 4 (7) | 3 (6) | 0.559 |
Duration, days | 0.4 ± 2 | 0.3 ± 2 | 0.785 |